Despite continued weakness and share shifts in Q219, the SCS market is poised to accelerate in H219 on new products/clinical data
In Q219, US and WW spinal cord stimulation (SCS) revenues were down for all the big players against tough YoY comps and ongoing weakness in the market as companies work through a gap in new product introductions, ongoing commercial execution issues and customer destocking. In the US, SCS revenues were down -6.3% vs Q218 according to the SmartTRAK Financial Dashboard. Although revenues were up sequentially per the usual seasonality in Q2, QoQ growth in Q219 was more anemic compared to the previous year. Between Q119-Q219, US SCS revenue was up just over ...
Among the many topics covered in the complete Q219 SCS Market Recap* are:
- Comprehensive Market Overview
- Market Expected to Accelerate
- Abbott Gains Share Despite YoY Decline
- Medtronic Drops to No. 3
- Boston SCS Down Against Tough Comps
- Nevro Aims for Relaunch
- Nuvectra--Exploring its Options
-
Q219 Regulatory/Clinical News
WW, SCS revenues followed a similar pattern in Q219, down -6.5% YoY vs Q218. Sequentially, WW SCS revenues were essentially flat QoQ in H119, vs ~9% QoQ growth between Q118-Q218 according to SmartTRAK Financial Dashboard.
Amid these dynamics, shares shifted in the quarter in both the US and WW. Based on Q219 US revenues, Abbott (ABT) regained the title of US SCS market leader over Boston Scientific (BSX), with revenues of ...
Read the entire Q219 SCS Market Recap including news, data, charts, company revenues and analysis*...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
